JANSSEN Alzheimer Immunotherapy Research & Development
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, JANSSEN Alzheimer Immunotherapy Research & Development sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,751 sponsors by registered trial count).
JANSSEN Alzheimer Immunotherapy Research & Development: 8 sponsored US clinical trials, none currently recruiting.
JANSSEN Alzheimer Immunotherapy Research & Development sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimers Disease, with 1 trials.
Upper-quartile sponsor footprint
JANSSEN Alzheimer Immunotherapy Research & Development sits in the upper quartile of the sponsor corpus (#1,604 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
NCT01284387
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
NCT01254773
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
NCT00937352
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
NCT00575055
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
NCT00574132
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
NCT00606476
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
NCT00112073
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
NCT00021723
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 3 |
Therapeutic Areas
How the JANSSEN Alzheimer Immunotherapy Research & Development early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).
Phase mix: 3 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Alzheimers Disease (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.